NovaBridge Biosciences (NBP) Non-Current Deffered Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has 5 years of Non-Current Deffered Revenue data on file, last reported at $40.6 million in Q4 2023.

• Quarterly Non-Current Deffered Revenue rose 7.72% year-over-year to $40.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $40.6 million (up 7.72% YoY) and the FY2023 annual result came in at $41.2 million, up 1618.54% from the prior year.
• Non-Current Deffered Revenue advanced to $40.6 million in Q4 2023 per NBP's latest filing, from $36.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $40.6 million in Q4 2023 and bottomed at $556172.6 in Q4 2019.
• The 4-year median for Non-Current Deffered Revenue is $36.9 million (2023), against an average of $30.1 million.
• The widest annual swing landed in 2019, when Non-Current Deffered Revenue surged 53.82%; it then advanced 7.5% in 2022.
• Tracing NBP's Non-Current Deffered Revenue over 4 years: stood at $556172.6 in 2019, then jumped by 6199.44% to $35.0 million in 2021, then gained by 7.5% to $37.7 million in 2022, then climbed by 7.72% to $40.6 million in 2023.
• Per Business Quant, the three latest NBP Non-Current Deffered Revenue figures stand at $40.6 million (Q4 2023), $36.9 million (Q2 2023), and $37.7 million (Q4 2022).

Peer Comparison